Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory...
Saved in:
Published in | Frontiers in immunology Vol. 4; p. 453 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
01.01.2013
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2013.00453 |
Cover
Abstract | Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index. |
---|---|
AbstractList | Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC) with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry (DXA) to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p= 0.01) while visceral fat was also increased, but only in women (p=0.01). Patients with AS tended to have lower total fat mass (p=0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index. Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA ( p = 0.01) while visceral fat was also increased, but only in women ( p = 0.01). Patients with AS tended to have lower total fat mass ( p = 0.07) and higher lean mass compared to HC ( p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS ( p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA ( p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index. Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index. |
Author | Toussirot, Éric |
AuthorAffiliation | 2 Department of Rheumatology, University Hospital of Besançon , Besançon , France 6 University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France 11 Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France 10 Université de Franche Comté, UMR1098 , Besançon , France 9 Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France 3 Department of Therapeutics, University of Franche Comté , Besançon , France 1 University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France 5 LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France 8 UMR1098, INSERM , Besançon , France 7 University of Franche Comté, UPRES EA 3920 “Cardiovascular Pathophysiology and Prevention”, SFR FED 4234 , Besançon , France 4 University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France |
AuthorAffiliation_xml | – name: 7 University of Franche Comté, UPRES EA 3920 “Cardiovascular Pathophysiology and Prevention”, SFR FED 4234 , Besançon , France – name: 2 Department of Rheumatology, University Hospital of Besançon , Besançon , France – name: 10 Université de Franche Comté, UMR1098 , Besançon , France – name: 11 Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France – name: 4 University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France – name: 9 Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France – name: 5 LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France – name: 3 Department of Therapeutics, University of Franche Comté , Besançon , France – name: 6 University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France – name: 1 University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France – name: 8 UMR1098, INSERM , Besançon , France |
Author_xml | – sequence: 1 givenname: Eric surname: Toussirot fullname: Toussirot, Eric organization: University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France ; Department of Rheumatology, University Hospital of Besançon , Besançon , France ; Department of Therapeutics, University of Franche Comté , Besançon , France ; University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France ; LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France – sequence: 2 givenname: Emilie surname: Grandclément fullname: Grandclément, Emilie organization: University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France ; University of Franche Comté, UPRES EA 3920 "Cardiovascular Pathophysiology and Prevention", SFR FED 4234 , Besançon , France – sequence: 3 givenname: Béatrice surname: Gaugler fullname: Gaugler, Béatrice organization: LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France ; UMR1098, INSERM , Besançon , France ; Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France ; Université de Franche Comté, UMR1098 , Besançon , France – sequence: 4 givenname: Fabrice surname: Michel fullname: Michel, Fabrice organization: Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France – sequence: 5 givenname: Daniel surname: Wendling fullname: Wendling, Daniel organization: Department of Rheumatology, University Hospital of Besançon , Besançon , France ; University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France – sequence: 6 givenname: Philippe surname: Saas fullname: Saas, Philippe organization: University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France ; LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France ; UMR1098, INSERM , Besançon , France ; Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France ; Université de Franche Comté, UMR1098 , Besançon , France – sequence: 7 givenname: Gilles surname: Dumoulin fullname: Dumoulin, Gilles organization: University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France ; University of Franche Comté, UPRES EA 3920 "Cardiovascular Pathophysiology and Prevention", SFR FED 4234 , Besançon , France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24379815$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uktv1DAQtlARLaV3TshHLrvEzzgXpKriUakSB-BsOfZk121iB9up2H-Pd7dFLRK-2DPzPWTN9xqdhBgAobekWTOmug-Dn6ZlTRvC1k3DBXuBzoiUfMUo5SdP3qfoIufbph7eMcbEK3RKOWs7RcQZ-v0d0jJh4_wc73yAjE1wxzIDLj7nBbDzuSTfL8XHgH3AaQvLZEr0FZnKNvmKO_LC3W6M2YcNznMMbjfuR2t8iW2cZpNM8feAc1nc7g16OZgxw8XDfY5-fv704-rr6ubbl-ury5uV5ZKWFeFCGMII67nqyFCb0DDLwMreSsdE6_ggnOUWWqCuVc4y6TgQqYAZKYCdo-ujrovmVs_JTybtdDReHxoxbXT9g7cjaE7sQMBSkIpxB9XQKmVhGFrVU2dp1fp41JqXfgJnIZRkxmeizyfBb_Um3mumJGkVqQLvHwRS_LVALnry2cI4mgBxyZrwrmklFYJV6LunXn9NHldXAfIIsCnmnGDQ1hezX1G19qMmjd7HRB9iovcx0YeYVGLzD_FR-7-UPw4pxWU |
CitedBy_id | crossref_primary_10_1080_25785826_2021_1948689 crossref_primary_10_1016_j_canlet_2018_03_011 crossref_primary_10_1016_j_lpm_2015_03_023 crossref_primary_10_3390_biomedicines11020536 crossref_primary_10_3390_biomedicines11112998 crossref_primary_10_3389_fendo_2019_00252 crossref_primary_10_1007_s00403_017_1755_y crossref_primary_10_3899_jrheum_140439 crossref_primary_10_1007_s10067_015_2955_5 crossref_primary_10_1517_14740338_2015_1007041 crossref_primary_10_3389_fendo_2020_606560 crossref_primary_10_5114_reum_2015_53998 crossref_primary_10_3390_ijms20184633 crossref_primary_10_3390_ijms23052859 crossref_primary_10_1002_jcla_22595 crossref_primary_10_1016_j_intimp_2017_09_029 crossref_primary_10_1016_j_lfs_2015_05_001 crossref_primary_10_1177_0300060517708693 crossref_primary_10_1016_j_monrhu_2017_11_003 crossref_primary_10_1186_ar4538 crossref_primary_10_1186_ar4537 crossref_primary_10_1016_j_rhum_2015_08_003 crossref_primary_10_3899_jrheum_140780 crossref_primary_10_1002_ajhb_22583 crossref_primary_10_1016_j_crad_2018_06_008 crossref_primary_10_1016_j_lfs_2017_12_003 crossref_primary_10_1016_j_jbspin_2015_04_010 crossref_primary_10_4078_jrd_2023_0005 crossref_primary_10_1177_20503121221085821 crossref_primary_10_1186_s13075_017_1350_9 crossref_primary_10_3390_ijms19092717 crossref_primary_10_3389_fimmu_2021_665208 crossref_primary_10_3889_oamjms_2022_8208 crossref_primary_10_3899_jrheum_170094 crossref_primary_10_1136_postgradmedj_2018_136372 crossref_primary_10_3389_fmed_2021_782150 crossref_primary_10_1093_rheumatology_keaa720 crossref_primary_10_1016_j_cyto_2015_04_004 crossref_primary_10_1016_j_arcmed_2016_03_001 |
ContentType | Journal Article |
Copyright | Copyright © 2013 Toussirot, Grandclément, Gaugler, Michel, Wendling, Saas, Dumoulin and CBT-506. 2013 |
Copyright_xml | – notice: Copyright © 2013 Toussirot, Grandclément, Gaugler, Michel, Wendling, Saas, Dumoulin and CBT-506. 2013 |
CorporateAuthor | CBT-506 |
CorporateAuthor_xml | – name: CBT-506 |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2013.00453 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_41cf1ec2e6834de489c88ceff78b2dc2 PMC3861781 24379815 10_3389_fimmu_2013_00453 |
Genre | Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE IPNFZ KQ8 M48 M~E OK1 PGMZT RIG RNS RPM NPM 7X8 5PM |
ID | FETCH-LOGICAL-c462t-1455a1313b4891fc46e03c3ec6bc6d357d4f5dc4ce7e2d78dc36d4e168e3a65e3 |
IEDL.DBID | M48 |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:01:21 EDT 2025 Thu Aug 21 14:10:12 EDT 2025 Fri Sep 05 12:40:19 EDT 2025 Thu Apr 03 06:55:42 EDT 2025 Thu Apr 24 22:57:09 EDT 2025 Tue Jul 01 01:57:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | adiponectin body composition cardiovascular risk leptin visceral fat fat mass |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-1455a1313b4891fc46e03c3ec6bc6d357d4f5dc4ce7e2d78dc36d4e168e3a65e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Inflammation, a section of the journal Frontiers in Immunology. Reviewed by: Giamila Fantuzzi, University of Illinois at Chicago, USA; Frédéric Velard, Université de Reims Champagne-Ardenne, France Edited by: Oreste Gualillo, Santiago University Clinical Hospital, Spain |
OpenAccessLink | https://doaj.org/article/41cf1ec2e6834de489c88ceff78b2dc2 |
PMID | 24379815 |
PQID | 1490762553 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_41cf1ec2e6834de489c88ceff78b2dc2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3861781 proquest_miscellaneous_1490762553 pubmed_primary_24379815 crossref_citationtrail_10_3389_fimmu_2013_00453 crossref_primary_10_3389_fimmu_2013_00453 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-01-01 |
PublicationDateYYYYMMDD | 2013-01-01 |
PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2013 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | 16732021 - Diabetes Care. 2006 Jun;29(6):1357-62 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24 19714593 - Arthritis Rheum. 2009 Sep 15;61(9):1248-56 6426576 - Br Med J (Clin Res Ed). 1984 May 12;288(6428):1401-4 16603581 - Rheumatology (Oxford). 2006 Nov;45(11):1385-8 19565493 - Arthritis Rheum. 2009 Jul;60(7):1906-14 15292530 - Rheumatology (Oxford). 2004 Oct;43(10):1219-23 18512711 - Arthritis Rheum. 2008 Jun 15;59(6):807-15 23806868 - Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72 17260105 - Clin Rheumatol. 2007 Sep;26(9):1427-32 23666343 - Biogerontology. 2013 Jun;14(3):261-72 17456023 - Curr Med Chem. 2007;14(10):1095-100 18759279 - Arthritis Rheum. 2008 Sep;58(9):2632-41 9159537 - Br J Rheumatol. 1997 Apr;36(4):444-8 6231933 - Arthritis Rheum. 1984 Apr;27(4):361-8 21292736 - Rheumatology (Oxford). 2011 Jul;50(7):1250-8 11296956 - J Rheumatol. 2001 Mar;28(3):547-9 24043573 - Horm Metab Res. 2014 Jan;46(1):41-7 17343838 - Clin Chim Acta. 2007 May 1;380(1-2):24-30 22282048 - Obesity (Silver Spring). 2012 Jun;20(6):1313-8 14623951 - Rheumatology (Oxford). 2004 Mar;43(3):306-10 15466894 - Rheumatology (Oxford). 2005 Jan;44(1):120-5 20959355 - Rheumatology (Oxford). 2011 Mar;50(3):450-62 21140266 - Rheumatol Int. 2012 Mar;32(3):699-702 16414972 - Ann Rheum Dis. 2006 Sep;65(9):1198-201 21618146 - Swiss Med Wkly. 2011 May 27;141:w13211 19602478 - Rheumatology (Oxford). 2009 Sep;48(9):1128-32 22876925 - Curr Med Chem. 2012;19(32):5474-80 17884449 - Metabolism. 2007 Oct;56(10):1383-9 12933646 - Endocrinology. 2003 Sep;144(9):3765-73 3899825 - Diabetologia. 1985 Jul;28(7):412-9 22213726 - Arthritis Care Res (Hoboken). 2012 Jan;64(1):101-7 11762933 - Arthritis Rheum. 2001 Dec;44(12):2737-45 1464859 - J Rheumatol. 1992 Oct;19(10):1505-10 22949540 - Circulation. 2012 Sep 4;126(10):1301-13 22584415 - Eur J Nutr. 2012 Aug;51(5):513-28 21567382 - Arthritis Rheum. 2011 Sep;63(9):2567-74 11511757 - Rheumatology (Oxford). 2001 Aug;40(8):882-8 15890981 - Circ Res. 2005 May 13;96(9):939-49 |
References_xml | – reference: 15890981 - Circ Res. 2005 May 13;96(9):939-49 – reference: 20959355 - Rheumatology (Oxford). 2011 Mar;50(3):450-62 – reference: 17884449 - Metabolism. 2007 Oct;56(10):1383-9 – reference: 22213726 - Arthritis Care Res (Hoboken). 2012 Jan;64(1):101-7 – reference: 23666343 - Biogerontology. 2013 Jun;14(3):261-72 – reference: 19565493 - Arthritis Rheum. 2009 Jul;60(7):1906-14 – reference: 22584415 - Eur J Nutr. 2012 Aug;51(5):513-28 – reference: 21140266 - Rheumatol Int. 2012 Mar;32(3):699-702 – reference: 17343838 - Clin Chim Acta. 2007 May 1;380(1-2):24-30 – reference: 11762933 - Arthritis Rheum. 2001 Dec;44(12):2737-45 – reference: 19602478 - Rheumatology (Oxford). 2009 Sep;48(9):1128-32 – reference: 18759279 - Arthritis Rheum. 2008 Sep;58(9):2632-41 – reference: 24043573 - Horm Metab Res. 2014 Jan;46(1):41-7 – reference: 23806868 - Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72 – reference: 21567382 - Arthritis Rheum. 2011 Sep;63(9):2567-74 – reference: 16603581 - Rheumatology (Oxford). 2006 Nov;45(11):1385-8 – reference: 16414972 - Ann Rheum Dis. 2006 Sep;65(9):1198-201 – reference: 21292736 - Rheumatology (Oxford). 2011 Jul;50(7):1250-8 – reference: 16732021 - Diabetes Care. 2006 Jun;29(6):1357-62 – reference: 11511757 - Rheumatology (Oxford). 2001 Aug;40(8):882-8 – reference: 19714593 - Arthritis Rheum. 2009 Sep 15;61(9):1248-56 – reference: 22282048 - Obesity (Silver Spring). 2012 Jun;20(6):1313-8 – reference: 15466894 - Rheumatology (Oxford). 2005 Jan;44(1):120-5 – reference: 22949540 - Circulation. 2012 Sep 4;126(10):1301-13 – reference: 22876925 - Curr Med Chem. 2012;19(32):5474-80 – reference: 11296956 - J Rheumatol. 2001 Mar;28(3):547-9 – reference: 9159537 - Br J Rheumatol. 1997 Apr;36(4):444-8 – reference: 6426576 - Br Med J (Clin Res Ed). 1984 May 12;288(6428):1401-4 – reference: 3899825 - Diabetologia. 1985 Jul;28(7):412-9 – reference: 1464859 - J Rheumatol. 1992 Oct;19(10):1505-10 – reference: 15292530 - Rheumatology (Oxford). 2004 Oct;43(10):1219-23 – reference: 18512711 - Arthritis Rheum. 2008 Jun 15;59(6):807-15 – reference: 21618146 - Swiss Med Wkly. 2011 May 27;141:w13211 – reference: 6231933 - Arthritis Rheum. 1984 Apr;27(4):361-8 – reference: 14623951 - Rheumatology (Oxford). 2004 Mar;43(3):306-10 – reference: 12933646 - Endocrinology. 2003 Sep;144(9):3765-73 – reference: 17456023 - Curr Med Chem. 2007;14(10):1095-100 – reference: 17260105 - Clin Rheumatol. 2007 Sep;26(9):1427-32 – reference: 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24 |
SSID | ssj0000493335 |
Score | 2.2214012 |
Snippet | Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 453 |
SubjectTerms | Adiponectin Body Composition fat mass Immunology Leptin visceral fat |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SEHwR6-fZKhF88WG9zedmH2tpKYI-Wejbkk0m3Fpvr9ztgv3vm0m2552Ivvi42QkJM5PMTDL5DSHvpbWls8EUkldlIXVbFzUPrDCuEjZ6dMwzfDv85au-uJSfr9TVTqkvzAnL8MCZcXPJXGDgOGgjpAdpameMgxAq03Lv0u4bzdhOMPU9-71CCJXvJWMUVs9Dt1yOmMqFiKZSiT07lOD6_-Rj_p4quWN7zp-Qx5PTSE_yZA_JA-ifkoe5jOTtM_IzLvhxSa3vblbXmMZObe_z5wbokFhLPSLkTsWtaNfT9QLG6K2uuki5HhYJ2yj3669jEI9HCBTTZ_0tJshtPtIT6n4hhdMES_ucXJ6ffTu9KKaKCoWTmg8FopJbJphoIx9ZiI1QCifA6dZpL1TlZVDeSQcVcF8Z74T2Epg2IKxWIF6Qg37VwytCrRFljWAzQdTRCWFWOwU8UhmoOQvljMzv-du4CW4cq178aGLYgRJpkkQalEiTJDIjH7Y9bjLUxl9oP6HItnQIkp0aouo0k-o0_1KdGXl3L_AmLiq8KbE9rMZNjIfqMloJhQO9zAqwHSohOBqmZqTaU429uez_6btFAu4WBh9kstf_Y_JH5BFPlTnwNOiYHAzrEd5E_2ho36alcAershOH priority: 102 providerName: Directory of Open Access Journals |
Title | Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24379815 https://www.proquest.com/docview/1490762553 https://pubmed.ncbi.nlm.nih.gov/PMC3861781 https://doaj.org/article/41cf1ec2e6834de489c88ceff78b2dc2 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: GX1 dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1664-3224 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M48 dateStart: 20101001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagCIkL4s0WqIzEhUPa-BHHOSBUEKVCKidW2lvk9YMN7SYlm0jdf98ZJ92yaIXEJVKccRx7xpkZe_wNIe-kMak1QSeS52ki1bxICh5Yom0uDFh0zDE8O3z2XZ1O5bdZNrs9Hj0O4Gqna4f5pKbtxeHV7_VHmPAf0OMEfXsUquWyxygtBCuVmbhL7oFe4ijjZ6Ox_2uwhYWIGTeZUjIBSZbDvuXOl2zpqQjnv8sG_TuU8g_ddPKIPByNSno8SMFjcsfXT8j9Ic3k-im5gh9Cv6TGVZfNOYa5U1O74XblaReHnjpE0B2TX9Gqpu3C92DNNhVQtt0iYh8N9epzcPJxiYFieK1bYwDd6pAeU3uLJE4jbO0zMj358uPzaTJmXEisVLxLELXcMMHEXOqCBSj0qbDCWzW3yoksdzJkzkrrc89drp0VyknPlPbCqMyL52Svbmr_klCjRVogGE0QBRgpzCibeQ5U2hechXRCjm7Gt7QjHDlmxbgowS1BjpSRIyVypIwcmZD3mxqXAxTHP2g_Ics2dAiiHQua9mc5zslSMhuYt9wrLaTz0GWrtfUh5HrOneUT8vaG4SVMOtxJMbVv-hX4S0UKWiTDhl4MArBpKiI8apZNSL4lGlvfsv2krhYR2FtoPLDJ9v-jo6_IAx4TdOCi0Guy17W9fwNmUjc_iMsLcP06YwdxJlwDpYsVIQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+adipokines+and+adipose+tissue+distribution+in+rheumatoid+arthritis+and+ankylosing+spondylitis.+A+comparative+study&rft.jtitle=Frontiers+in+immunology&rft.au=Toussirot%2C+%C3%89ric&rft.date=2013-01-01&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=4&rft_id=info:doi/10.3389%2Ffimmu.2013.00453&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2013_00453 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |